HDAC9 and head and neck squamous cell carcinoma: Given that HDAC inhibitors are currently being tested in clinical trials for head and neck squamous cell carcinomas and the demonstrated synergism when combined with EGFR inhibitors [47,48], CHD4 could constitute a clinically relevant response biomarker (Figure 2b).